Most current models capture late stages of cancers, including AML. We wanted to develop a model that could capture the earlier stages and, in particular, track the progression from early stages to the fully developed Acute myeloid leukemia.
I think the main message here is that even among women with presumably favorable prognosis breast tumors (HR-positive, axillary node-negative), Black women die from their cancer at a significantly higher rate than women from most other racial/ethnic groups, even after controlling for treatment and known prognostic variables (including the Oncotype recurrence score).
Historically, investment and innovation in women’s health have been limited. However, Mycovia is committed to recognizing and empowering those living with unmet medical needs, which is one of the reasons we focused first on developing oteseconazole for recurrent vaginal yeast infections.
While the absolute magnitude of weight loss may seem low, it is important to remember that even small amounts of weight loss, even 3%-5% of body weight, can provide significant health benefits to individuals with overweight and obesity.
As a physician treating patients with difficult conditions like HRS-1, I am committed to continuing to build on decades of research of investigational products like terlipressin that can advance our scientific understanding of potential treatment options for these very sick patients who often rapidly decline and experience significant mortality rates if left untreated.
In May 2018, the FDA awarded Engensis the special breakthrough designation of RMAT (Regenerative Medicine Advanced Therapy) which is the first time for a pain medication and the first time for any type of medication used to treat a disease that affects a large part of the U.S. population.
This study generates new evidence in support of a brain imaging biomarker that may help guide people suffering from post-traumatic stress disorder (PTSD) or major depressive disorder (MDD) towards the most effective treatment.
Dupilumab is a biologic therapy that works differently from existing therapies to address type 2 inflammation – an underlying cause of atopic dermatitis. Dupilumab is the only biologic approved for this pediatric population.
T-DXd has now been shown to be a powerful therapy for HER2+ advanced CRC after failure of standard therapies and its role in the strategy of treatment of colorectal cancer should be further investigated in earlier lines of therapy.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.